1. Search Result
Search Result
Results for "

Pro-PEG3-BA

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

7

Peptides

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P5112A

    Azido-PEG3-FLAG TFA

    Biochemical Assay Reagents Others
    Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) TFA is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
    Azido-PEG3-DYKDDDDK TFA
  • HY-180965

    PROTACs Anaplastic lymphoma kinase (ALK) EGFR Apoptosis Cancer
    Pro-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader, degrading EML4 ALK and EGFR mutant (L858R/T790M) with DC 50 values of 0.42 and 13.50 μM, respectively. Pro-PEG3-BA hinders proliferation and induces cell cycle arrest and apoptosis of NSCLC cells in vitro. Pro-PEG3-BA shows safety profile and decreases EML4-ALK protein via rewiring the ubiquitin- proteasome system in vivo. Pro-PEG3-BA can be used for non-small cell lung cancer research [3].
    Pro-PEG3-BA
  • HY-P5112

    Azido-PEG3-FLAG

    Biochemical Assay Reagents Others
    Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
    Azido-PEG3-DYKDDDDK
  • HY-169089

    Drug Derivative Cancer
    RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
    RP-182-PEG3-K(palmitic acid)-NH2
  • HY-169089A

    Drug Derivative Cancer
    RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
    RP-182-PEG3-K(palmitic acid)-NH2 TFA
  • HY-P10319

    PKA Cardiovascular Disease Cancer
    RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
    RI-STAD-2
  • HY-P11488

    Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-DOTA-PSMA-03
  • HY-P11485

    Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-HBED-CC-PSMA-03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: